# Avanos Medical, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Avanos Medical, Inc). ## Overview Avanos Medical, Inc. is a U.S.-based medical technology company focused on products that support enteral nutrition and pain management/recovery. Its portfolio is centered on helping patients move from hospital to home and from surgery to recovery, with brands such as MIC-KEY and Corpak in specialty nutrition. The company develops, manufactures, and markets its products globally and sells primarily to healthcare providers through distributors and group purchasing organizations. Avanos has been reshaping its portfolio through divestitures, asset sales, restructuring, and targeted acquisitions to concentrate on its two core operating segments. ## Products & services • Enteral feeding tubes and feeding systems • MIC-KEY enteral feeding tubes • Corpak patient feeding solutions • Radiofrequency ablation (RFA) pain solutions • Surgical pain and recovery products • Specialty nutrition systems for hospital-to-home care • Distribution and clinical support to healthcare providers - **Specialty Nutrition Systems** (57%) — Enteral nutrition products used to provide feeding access and support patients from hospital to home. - **Pain Management and Recovery** (34%) — Products and devices used to reduce pain and support recovery after surgery or procedures. - **Legacy / Divested and Transitioning Products** (9%) — Products and asset lines being exited or transitioned as part of portfolio rationalization. - Enteral feeding tubes and feeding systems - MIC-KEY enteral feeding tubes - Corpak patient feeding solutions - Radiofrequency ablation (RFA) pain solutions - Surgical pain and recovery products - Specialty nutrition systems for hospital-to-home care - Distribution and clinical support to healthcare providers ## Customers Avanos sells mainly to hospitals, ambulatory care centers, and other sites of care that need enteral feeding and pain-management devices. Physicians, nurses, hospital administrators, and professional societies influence product selection because the company’s products are used in clinical workflows and procedure settings. A meaningful portion of sales also flows through third-party wholesale distributors and group purchasing organizations, which matter because they negotiate pricing and purchasing access for provider networks. Outside North America, the company relies more heavily on distributors or wholesalers, reflecting local market structure and reimbursement practices. End customers ultimately include patients who need nutrition support or post-surgical pain solutions, but purchasing decisions are made by healthcare institutions and their procurement channels. - **Hospitals and health systems** (primary) — Buy enteral feeding and pain-management products for inpatient and procedural use because they need clinically reliable devices and standardized supply access. - **Ambulatory care centers and other sites of care** (secondary) — Purchase pain and recovery products and some nutrition solutions for outpatient procedures and post-acute care workflows. - **Group purchasing organizations** (primary) — Contract for access, pricing, and volume discounts on behalf of member providers, shaping Avanos pricing and distribution reach. - **Wholesale and strategic distribution partners** (primary) — Buy and resell products in North America and international markets where distributor-led channels are more efficient. - **Clinicians and care teams** (secondary) — Influence product adoption by selecting devices that fit clinical protocols, ease of use, and patient outcomes. - Hospitals buying enteral feeding and pain-management devices - Ambulatory care centers using products in outpatient procedures - Physicians and nurses influencing product choice and adoption - Group purchasing organizations negotiating access and pricing - Wholesale distributors reselling to healthcare facilities - Patients who receive nutrition support or recovery therapies ## Geography Avanos is headquartered in Alpharetta, Georgia and manufactures in the United States, Mexico, and Canada. Its distribution network spans North America, Europe, Australia, and Japan, which supports global commercialization of its medical device portfolio. North America is the largest revenue region, while Europe, the Middle East and Africa and Asia Pacific/Latin America provide additional international exposure. The company also relies on distributors more heavily outside North America, making regional channel structure and reimbursement conditions important to growth and margin performance. Portfolio changes and manufacturing footprint optimization are part of its transformation plan, so geography matters both for supply chain efficiency and for where the company can sell directly versus through partners. - **North America** (77.5%) — Based on 2025 net sales by geographic region. - **Europe, Middle East and Africa** (14.7%) — Based on 2025 net sales by geographic region. - **Asia Pacific and Latin America** (7.8%) — Based on 2025 net sales by geographic region. - Headquartered in Alpharetta, Georgia, United States - Manufacturing facilities in the United States, Mexico, and Canada - Distribution centers in North America, Europe, Australia, and Japan - North America is the largest revenue region at 77.5% of 2025 sales - EMEA contributed 14.7% of 2025 sales - Asia Pacific and Latin America contributed 7.8% of 2025 sales - International sales rely more heavily on distributors and wholesalers ## Strategy Avanos is executing a multi-year transformation focused on concentrating the business around Specialty Nutrition Systems and Pain Management and Recovery. Management has been rationalizing the portfolio through divestitures and asset sales, including the Respiratory Health divestiture, the sale of HA assets, and the exit from the Game Ready rental business. The company is also pursuing cost management, manufacturing and distribution footprint optimization, and business process efficiencies to improve operating profitability. At the same time, it is using acquisitions selectively, such as Nexus and Diros, to add capabilities that fit its strategic and financial criteria. - **Portfolio rationalization** (short-term) — Focusing on higher-value core categories should improve mix, simplify operations, and reduce management distraction from non-core businesses. - **Cost and footprint optimization** (medium-term) — Restructuring manufacturing, distribution, and overhead is intended to lift profitability after portfolio changes. - **Core-category growth** (medium-term) — SNS and PM&R are the company’s main growth and investment areas, supporting recurring clinical demand and brand relevance. - **Selective M&A** (medium-term) — Acquisitions can add technology or market access if they fit strategic and financial criteria. - Concentrate on SNS and PM&R as the core operating segments - Exit low-margin or non-core product lines to simplify the portfolio - Improve operating profitability through restructuring and cost control - Optimize manufacturing and distribution footprint after divestitures - Use selective acquisitions to strengthen core categories - Maintain global market positions in recognized branded products ## Risks Avanos operates in a highly competitive medical device market where price, clinical alternatives, innovation, and reputation all affect share. Its products are exposed to product liability claims, recalls, safety alerts, and regulatory actions because they are used in invasive or procedure-related settings. Reimbursement pressure from government programs and private insurers can reduce customer willingness to pay and can force pricing concessions, especially in cost-sensitive healthcare systems. The company also faces execution risk from its ongoing transformation, including divestitures, restructuring, and manufacturing footprint changes, which can disrupt supply or distract management. In addition, tariffs, foreign exchange, distributor concentration, and international channel dependence can affect margins and demand across regions. - **Competitive pressure in medical devices** [high] — The company competes against larger firms and niche specialists on price, innovation, and clinical preference, which can erode share or margins. - **Product liability and recall exposure** [high] — Devices used in patient care can trigger claims, recalls, or regulatory action if defects, misuse, or adverse events occur. - **Reimbursement and payor pressure** [medium] — Hospitals and providers may reduce purchases or demand discounts if reimbursement is constrained. - **Transformation and restructuring execution** [medium] — Portfolio exits and footprint changes can create operational disruption, one-time costs, and supply-chain complexity. - **Tariffs and cross-border cost inflation** [medium] — Manufacturing and distribution across multiple countries expose the company to trade policy and input-cost changes. - Intense competition from larger and specialized medical device rivals - Product liability, recalls, and regulatory actions tied to device safety - Reimbursement pressure from payors reducing pricing power - Execution risk from restructuring and portfolio transformation - Distributor concentration and channel dependence in key markets - Tariffs and foreign exchange volatility affecting costs and margins - International market variation in standards of care and adoption ## Accounting Avanos has several accounting areas that can materially affect reported results, especially during its transformation period. Revenue is influenced by distributor and GPO arrangements because fees paid to GPOs are recorded as reductions of net sales, and channel mix can shift the timing and amount of recognized revenue. The company also has meaningful judgment in goodwill and intangible asset impairment testing, highlighted by an interim goodwill impairment test in 2025 after market capitalization declined. Restructuring charges, divestiture accounting, discontinued operations, and asset-sale gains or losses can create large period-to-period swings that are not reflective of underlying operating demand. Investors should also watch estimates around product liability, litigation, and other contingencies, since these can affect expense recognition and reserves. - **GPO fees and net sales deductions** — Revenue and margin presentation - **Goodwill and intangible impairment** — Earnings, equity, and segment comparability - **Restructuring and transformation costs** — Operating profit and trend comparability - **Divestiture and discontinued operations accounting** — Reported revenue base and operating income - **Contingent liabilities and product liability reserves** — Expense recognition and balance sheet reserves - GPO fees reduce net sales and affect reported revenue - Distributor channel mix can change revenue timing and gross-to-net deductions - Goodwill and intangible impairment testing can create large non-cash charges - Restructuring costs affect operating expenses during the transformation plan - Divestitures and discontinued operations can distort year-over-year comparability - Product liability and legal contingencies require judgmental reserve estimates --- *Last updated: 2026-09-24T11:36:39.937154+00:00*